newsfilter
← Latest News
GlobeNewswire·

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score Company Plans to Submit a Special Protocol Assessment (SPA) APX3330 has the Potential to be the